US Edition
News from lasvegasoptic.com
We’ve assigned a media bias rating of Center to lasvegasoptic.com. You can read more about our methodology here.
Media Bias Ratings
Average Bias Rating:
Center
Center
byMedia Bias/Fact CheckDo you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top lasvegasoptic.com News
FDA · United StatesA voluntary recall has been issued for select pints of a dairy-free frozen dessert over concerns that they may contain “small stones and other hard objects,” according to a notice shared by the Food and Drug Administration (FDA).See the Story
Potential ‘small stones’ in frozen dessert prompt nationwide recall: FDA
88% Center coverage: 51 sources
Los Angeles, California · Los AngelesLOS ANGELES, Dec. 16, 2025 /PRNewswire/ -- Today, the MARRIAGETOXIN Project announced the release of an all-new main visual, first trailer, and additional main staff for the highly anticipated hitman x marriage swindler, battle-action series, MARRIAGETOXIN. The anime adaptation from BONES Film, known for My Hero Academia and Gachiakuta, welcomes Anna Nagase, Mariya Ise, Asaki Yuikawa, Soma Saito, Hinano Shirahama, and Simba Tsuchiya into its cas…See the Story
MARRIAGETOXIN Ties the Knot on New Visuals, First ...
90% Center coverage: 20 sources
San Francisco, California · San FranciscoSAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Stock Code: 2563.HK), today announced that the first patient has been dosed for one of its key oversea clinical studies:…See the Story
Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
83% Center coverage: 18 sources
